SYMBICORT TURBUHALER is indicated for:

• The treatment of asthma in patients 12 years and older with reversible obstructive airways disease.

SYMBICORT 200 TURBUHALER and SYMBICORT FORTE TURBUHALER are indicated for:

• The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.

Click here for additional safety information and for a link to the product monograph discussing:

• Contraindications in patients with hypersensitivity to inhaled lactose.
• The most serious warnings and precautions regarding risk of serious asthma-related events (hospitalizations, intubations, death), asthma reliever medication, excessive use, use in adolescents, systemic effects of corticosteroids, and treatment cessation.
• Other relevant warnings and precautions regarding treatment cessation; cardiovascular effects; candidiasis; hyperglycemia, hypokalemia; enhanced effect of corticosteroids on patients with hypothyroidism and cirrhosis; adrenal insufficiency in asthma patients transferred from systemic steroid; decreased bone mineral density; systemic eosinophilic conditions (in rare cases); susceptibility or decreased resistance to infection; glaucoma, increased intraocular pressure and cataracts; increased risk of pneumonia and risk of lung infection in patients with COPD; paradoxical bronchospasm; potential risk during pregnancy, labour, delivery or nursing; patients <12 years of age (asthma) and <18 years of age (COPD) (not recommended); patients >65 years of age with concomitant cardiovascular disease (use special caution); monitoring control of asthma; periodical assessment of HPA-axis function and hematological status.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing.
• Risks related to reproductive health, including teratogenic risk

COPD: chronic obstructive pulmonary disease; HPA: hypothalamic-pituitary-adrenal.